We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GDUFA II Fee Structure Shifts Revenue Model to ‘Predictable’ Annual Dues
GDUFA II Fee Structure Shifts Revenue Model to ‘Predictable’ Annual Dues
The FDA is proposing annual dues for sponsors of one or more approved ANDAs to guarantee a more predictable stream of funding that will raise revenues for the agency’s generics program starting in fiscal 2018.